dc.contributor
Universitat Ramon Llull. IQS
dc.contributor.author
Pontón, Iris
dc.contributor.author
Sánchez-García, David
dc.date.accessioned
2025-09-16T05:13:59Z
dc.date.available
2025-09-16T05:13:59Z
dc.date.issued
2025-08-01
dc.identifier.issn
2079-4991
dc.identifier.uri
http://hdl.handle.net/20.500.14342/5511
dc.description.abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers worldwide, characterized by late diagnosis, aggressive progression, and poor response to conventional monotherapies. Combination therapies have emerged as a promising approach to overcome multidrug resistance (MDR), enhance efficacy, and target the complex tumor microenvironment (TME). Nanoparticle-based drug delivery systems (DDSs) have gained significant attention for their ability to co-deliver multiple agents with controlled release profiles. This review comprehensively examines nanoparticle-based platforms developed for PDAC combination therapies, focusing on small-molecule drugs. The systems discussed are drawn from studies published between 2005 and 2025.
dc.relation.ispartof
Nanomaterials 2025, 15 (15), 1139
dc.rights
Attribution 4.0 International
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Pancreatic cancer
dc.subject
Pancreatic ductal adenocarcinoma
dc.subject
Combination therapy
dc.subject
Multi-drug resistance
dc.subject
Stromal therapy
dc.subject
Pàncrees--Càncer
dc.subject
Nanopartícules
dc.subject
Terapia combinada
dc.subject
Resistència als medicaments
dc.title
Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
dc.type
info:eu-repo/semantics/article
dc.description.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
https://doi.org/10.3390/nano15151139
dc.rights.accessLevel
info:eu-repo/semantics/openAccess
